16Feb/13

NOVARTIS AG : Novartis drug Zortress® is first in over a decade approved by … – 4-traders (press release)

NOVARTIS AG : Novartis drug Zortress® is first in over a decade approved by
4-traders (press release)
Basel, February 15, 2013 – Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress® (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant. Zortress is the first
FDA Nod For Novartis Drug To Avert Organ Failure In Liver TransplantRTT News
US FDA okays Novartis drug to prevent liver transplant rejectionReuters

all 3 news articles »

16Feb/13

FDA approves Novartis' Zortress to prevent organ rejection in adults after … – News-Medical.net

FDA approves Novartis’ Zortress to prevent organ rejection in adults after
News-Medical.net
“Novartis has been a leading innovator in the transplant field for 30 years, and this FDA approval for liver transplantation marks an important milestone for patients and their transplant physicians in the US,” said David Epstein , Division Head of
FDA Nod For Novartis Drug To Avert Organ Failure In Liver TransplantRTT News

all 3 news articles »